Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: Six-month results from the prague-15 study

Hypertension

Volumn 65, Issue 2, 2015, Pages 407-413

  Rosa, Ján ^a,b   Widimský, Petr ^b   Toušek, Petr ^b   Petrák, Ondřej ^a   Čurila, Karol ^c   Waldauf, Petr ^c   Bednář, František ^b   Zelinka, Tomáš ^a   Holaj, Robert ^a   Štrauch, Branislav ^a   Šomlóová, Zuzana ^a   Táborský, Miloš ^c   Václavík, Jan ^c   Kociánová, Eva ^b,c   Branny, Marian ^d   Nykl, Igor ^d   Jiravský, Otakar ^d   Widimský, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d Cardiocentre   (Czech Republic)

Author keywords

hypertension resistant to conventional therapy; spironolactone; sympathetic denervation

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; POTASSIUM; SARTAN DERIVATIVE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; ANTIHYPERTENSIVE THERAPY; ARTERIOVENOUS FISTULA; ARTERY DISSECTION; ARTICLE; ASYMPTOMATIC BRADYCARDIA; BLOOD PRESSURE MONITORING; BODY MASS; BRADYCARDIA; BRAIN ISCHEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEPRESSED BLOOD PRESSURE; DRUG THERAPY; DRUG WITHDRAWAL; FALSE ANEURYSM; FEMALE; FOLLOW UP; HEART INFARCTION; HEART RATE; HUMAN; HYPERKALEMIA; INTERMETHOD COMPARISON; KIDNEY DENERVATION; KIDNEY DENERVATION SYSTEM; KIDNEY DISEASE; LARYNX SPASM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; OPEN STUDY; OPTIMAL DRUG DOSE; PHLEBITIS; POSTPUNCTUAL PSEUDOANEURYSM; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY DISSECTION; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; CATHETER ABLATION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; HYPERTENSION; INNERVATION; KIDNEY; METABOLIC CLEARANCE RATE; NERVE FIBER TRANSECTION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; SYMPATHECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AXOTOMY; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETER ABLATION; CREATININE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SPIRONOLACTONE; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84921596261     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04019     Document Type: Article

References (19)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
2. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
3. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.
4. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976-2982.
5. Widimský P, Filipovský J, Widimský Jr J, Branny M, Monhart V, Táborský M. Expert consensus statement of the Czech Society of Cardiology and the Czech Society of Hypertension on catheter-based sympathetic renal denervation procedures (RDN) in the Czech Republic. Cor et Vasa. 2012;54:e108-e112.
6. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnass E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63:991-999.
7. Toušek P, Widimský Jr J, Rosa J, urila K, Branny M, Nykl I, Táborský M, Václavík J, Widimský P. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. Cor et Vasa. 2014;56:e228-e234.
8. Rosa J, Zelinka T, Petrák O, Štrauch B, Šomlóová Z, Indra T, Holaj R, urila K, Toušek P, Šenitko M, Widimský P, Widimský Jr J. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically J Hum Hypertens. 2014; 28:684-688.
9. Štrauch B, Petrák O, Zelinka T, Rosa J, Šomlóová Z, Indra T, Chytil L, Marešová V, Kurcová I, Holaj R, Wichterle D, Widimský J Jr. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455-2461.
10. urila K, Rosa J, Toušek P, Widimský Jr J, Widimský P. Technical and safety aspects of renal denervation. Cor et Vasa. 2014;56:e228-e234.
11. Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension. 2013;62:450-452.
12. Persu A, Jin Y, Azizi M, et al. . Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150-156.
13. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
14. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-774.
15. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147-152.
16. Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-1075.
17. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2:462-468.
18. Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, Laufs U, Neuberger HR, Böhm M. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2013;167:2846-2851.
19. Persu A, Jin Y, Baelen M, et al. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension. 2014;63:1319-1325.